Cantor Fitzgerald Reaffirms “Overweight” Rating for Vera Therapeutics (NASDAQ:VERA)

Cantor Fitzgerald restated their overweight rating on shares of Vera Therapeutics (NASDAQ:VERA) in a report published on Monday morning, Benzinga reports. They currently have a $107.00 target price on the stock.

Separately, JPMorgan Chase & Co. lifted their price objective on Vera Therapeutics from $62.00 to $72.00 and gave the stock an overweight rating in a report on Tuesday, September 3rd. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Vera Therapeutics presently has an average rating of Buy and a consensus target price of $51.75.

Vera Therapeutics Stock Up 0.8 %

VERA stock opened at $40.33 on Monday. Vera Therapeutics has a 1-year low of $9.24 and a 1-year high of $50.78. The business has a fifty day moving average price of $37.26 and a 200-day moving average price of $39.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.43 and a quick ratio of 21.43. The stock has a market capitalization of $2.21 billion, a P/E ratio of -19.67 and a beta of 0.99.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Equities analysts forecast that Vera Therapeutics will post -2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 15,625 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total transaction of $585,937.50. Following the completion of the sale, the chief executive officer now owns 307,972 shares of the company’s stock, valued at $11,548,950. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 21.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Vera Therapeutics

Institutional investors have recently made changes to their positions in the business. William Marsh Rice University purchased a new stake in shares of Vera Therapeutics during the second quarter worth about $593,000. Cambridge Trust Co. grew its position in shares of Vera Therapeutics by 386.6% during the first quarter. Cambridge Trust Co. now owns 48,107 shares of the company’s stock worth $2,074,000 after purchasing an additional 38,220 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Vera Therapeutics during the first quarter worth about $9,727,000. Jennison Associates LLC bought a new position in Vera Therapeutics during the first quarter valued at approximately $3,231,000. Finally, Vanguard Group Inc. boosted its stake in Vera Therapeutics by 31.5% during the first quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock valued at $92,653,000 after buying an additional 515,106 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.